146 related articles for article (PubMed ID: 36792544)
1. Immune response to ART initiation in advanced HIV infection.
Mounzer K; Brunet L; Fusco JS; McNicholl IR; Dunbar M; Sension M; McCurdy LH; Fusco GP
HIV Med; 2023 Jun; 24(6):716-726. PubMed ID: 36792544
[TBL] [Abstract][Full Text] [Related]
2. Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens.
Mounzer K; Brunet L; Fusco JS; Mcnicholl IR; Diaz Cuervo H; Sension M; Mccurdy L; Fusco GP
Open Forum Infect Dis; 2022 Mar; 9(3):ofac018. PubMed ID: 35169590
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety profiles of dolutegravir plus lamivudine vs . bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1.
Wei Y; Li J; Xu R; Wen L; Deng Y; He L; Zhong H; Wang Y
Chin Med J (Engl); 2023 Nov; 136(22):2677-2685. PubMed ID: 37914678
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study.
Lee CY; Lee CH; Tang HJ; Tsai HC; Yang CH; Lin YP; Wang SF; Lu PL
Infect Dis Ther; 2023 Mar; 12(3):843-861. PubMed ID: 36520332
[TBL] [Abstract][Full Text] [Related]
5. Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV.
Hsu RK; Brunet L; Fusco JS; Mounzer K; Lamori JC; Fusco GP
AIDS Res Hum Retroviruses; 2022 Oct; 38(10):782-791. PubMed ID: 35923143
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study.
Alejos B; Suárez-García I; Rava M; Bautista-Hernández A; Gutierrez F; Dalmau D; Sagastagoitia I; Rivero A; Moreno S; Jarrín I;
J Antimicrob Chemother; 2020 Oct; 75(10):3004-3014. PubMed ID: 32667674
[TBL] [Abstract][Full Text] [Related]
7. Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
Hoffmann C; Schewe K; Fenske S; Buhk T; Sabranski M; Adam A; Hansen S; Stellbrink HJ
Antivir Ther; 2020; 25(2):83-90. PubMed ID: 32235038
[TBL] [Abstract][Full Text] [Related]
8. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
[TBL] [Abstract][Full Text] [Related]
9. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
Sax PE; Rockstroh JK; Luetkemeyer AF; Yazdanpanah Y; Ward D; Trottier B; Rieger A; Liu H; Acosta R; Collins SE; Brainard DM; Martin H;
Clin Infect Dis; 2021 Jul; 73(2):e485-e493. PubMed ID: 32668455
[TBL] [Abstract][Full Text] [Related]
10. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
[TBL] [Abstract][Full Text] [Related]
11. Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
Acosta RK; Chen GQ; Chang S; Martin R; Wang X; Huang H; Brainard D; Collins SE; Martin H; White KL
J Antimicrob Chemother; 2021 Jul; 76(8):2153-2157. PubMed ID: 33880558
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Suárez-García I; Alejos B; Hernando V; Viñuela L; Vera García M; Rial-Crestelo D; Pérez Elías MJ; Albendín Iglesias H; Peraire J; Tiraboschi J; Díaz A; Moreno S; Jarrín I;
J Antimicrob Chemother; 2023 Jun; 78(6):1423-1432. PubMed ID: 37099559
[TBL] [Abstract][Full Text] [Related]
13. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR study.
Wong A; Brunetta J; De Wet J; Logue K; Loemba H; Saifi T; Mumm D; Marongiu A; Harrison R; Thorpe D; Trottier B
Medicine (Baltimore); 2024 Apr; 103(16):e37785. PubMed ID: 38640301
[TBL] [Abstract][Full Text] [Related]
14. A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China.
Zhong M; Li M; Qi M; Su Y; Yu N; Lv R; Ye Z; Zhang X; Xu X; Cheng C; Chen C; Wei H
Front Immunol; 2022; 13():1033098. PubMed ID: 36700216
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Imaz A; Podzamczer D
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
[TBL] [Abstract][Full Text] [Related]
16. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Orkin C; Eron JJ; Rockstroh J; Podzamczer D; Esser S; Vandekerckhove L; Van Landuyt E; Lathouwers E; Hufkens V; Jezorwski J; Opsomer M;
AIDS; 2020 Apr; 34(5):707-718. PubMed ID: 31833849
[TBL] [Abstract][Full Text] [Related]
17. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts.
Esser S; Brunetta J; Inciarte A; Levy I; D'Arminio Monforte A; Lambert JS; van Welzen B; Teruya K; Boffito M; Liu CE; Altuntas Aydın O; Thorpe D; Heinzkill M; Marongiu A; Cassidy T; Haubrich R; D'Amato L; Robineau O
HIV Med; 2024 Apr; 25(4):440-453. PubMed ID: 38148567
[TBL] [Abstract][Full Text] [Related]
18. HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial.
Bruzzesi E; Gabrieli A; Bernasconi D; Marchetti G; Calcagno A; Ripamonti D; Antinori A; Squillace N; Cingolani A; Muscatello A; Bandera A; Gori A; Rusconi S; Nozza S;
J Med Virol; 2023 Sep; 95(9):e29114. PubMed ID: 37752816
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters.
Corona D; Pérez-Valero I; Camacho A; Gutiérrez Liarte Á; Montero-Alonso M; Alemán MR; Ruiz-Seco P; Pérez González A; Riera M; Jarrin I; Rivero-Juárez A; Rivero A
Int J Antimicrob Agents; 2024 Jan; 63(1):107016. PubMed ID: 37890734
[TBL] [Abstract][Full Text] [Related]
20. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
